Crude rates for this follow-up of 2154 person-years were 2.2 (95% CI 1.5, 3.1) and 2.2 (95% CI 1.3, 3.3) episodes per 100 person-years for the atorvastatin and rosuvastatin groups respectively, without finding statistically significant differences between the two groups (crude models, adjusted for age and sex, and for major cardiovascular risk factors as described in methods). You're more likely to have side effects if you're a female, are 65 years or older, drink alcohol every day, or take more than one medicine for cholesterol. Domanski M, Lloyd-Jones D, Fuster V, Grundy S. Can we dramatically reduce the incidence of coronary heart disease? Can lower your risk of heart attack, stroke, and death, particularly if you have diabetes, high blood pressure, obesity, or a history of smoking. Slows down the buildup of fatty deposits in your blood vessels, otherwise known as a hardening of the arteries. This extreme is exceptional in the registry since the usual is the addition of ezetimibe in case of not achieving therapeutic goals, and the use of ezetimibe in both groups is well balanced . Lipitor (atorvastatin) improves your cholesterol levels and is a common first treatment for people with high cholesterol or heart disease. All authors contributed to the study conception and design. Atorvastatin provided greater protection against death or major cardiovascular events than pravastatin did. Among the patients in the registry with ASCVD (n = 407), 287 had their first episode in the last 15 years (year 2004 or later). Perez-Calahorra, S., Laclaustra, M., Marco-Benedi, V. et al. J Am Coll Cardiol. Given that subjects in secondary prevention have different clinical characteristics, such as the currently high prevalences of diabetes  and vascular revascularization  among them, and different concomitant medications, from subjects in primary prevention, it would be good to know whether the benefit of both statins is similar in secondary prevention in real life. This study does not find differences between high doses of rosuvastatin and atorvastatin in the recurrence of ASCVD, and supports their use as clinically equivalent in secondary prevention of ASCVD. Crestor (rosuvastatin) is one of the most effective statins to improve cholesterol. N Engl J Med. Evidence from genetic, epidemiologic, and clinical studies. statement and Privacy Lipids Health Dis 18, 216 (2019). Lipitor and Crestor are also used to reduce the risk of heart attacks, stroke, and arterial revascularization procedures in patients with multiple risk factors for heart disease. Part of Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. Crestor (generic name Rosuvastatin) and Lipitor (generic name Atorvastatin), are both statins, i.e., these drugs work to lower \"bad\" cholesterol (LDL), fats and triglycerides, in the blood. Diabetes was defined as fasting plasma glucose ≥126 mg/dl, HbA1c ≥6.5%, or self-reported treatment with antidiabetic medications. Comparative efficacy between atorvastatin and rosuvastatin in the prevention of cardiovascular disease recurrence. In order to analyze potential differences in the clinical response to atorvastatin and rosuvastatin in subjects in secondary ASCVD prevention, we have analyzed the clinical evolution of those subjects of the Dyslipemia Registry of the Spanish Society of Arteriosclerosis (SEA) who at the time of inclusion in the Registry had already suffered an ASCVD. Eur Heart J. 2005;294:2437–45. These 345 subjects accumulated 1050 person-years in a mean follow-up of 3 years. Total cholesterol and non-HDLc were higher before treatment in those subjects to whom rosuvastatin was prescribed. Crestor (rosuvastatin) isn't safe to use if you're pregnant since it can hurt the fetus. One central idea in ASCVD prevention is that the type and intensity of any preventive measure should be conditioned by the risk of developing ASCVD over time, especially in the short and medium term . Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Lowers "bad" cholesterol (LDL) and triglycerides (fats), and raises "good" cholesterol (HDL) in people who have trouble doing this through diet and exercise. Event rates were 2.73 (95% CI: 1.63, 4.25) cases/100 person-years and 2.34 (95% CI: 1.17, 4.10) cases/100 person-years in the atorvastatin and rosuvastatin groups, respectively.